Insights+: EMA Marketing Authorization of New Drugs in October 2023

Shots: The EMA approved 2 BLA while 7 new chemical Entity, 6 BLA received positive CHMP opinion in October 2023, leading to treatments for patients and advances in the healthcare industry In October 2023, the major highlight drugs were Keytruda + trastuzumab 1L treatment of LA unresectable or metastatic HER2+ gastric or GEJ adenocarcinoma &…

BySenior EditorNovember 23, 2023

TOP 20

Top 20 Prescription Drugs Based on 2022 Total Revenue

Shots: Prescription drugs have an instrumental role in effectively controlling chronic diseases like heart-related conditions, diabetes, arthritis, hypertension, and cancer, among others. Unlike over-the-counter drugs, prescription drugs are advised not to be taken without the authorization of a doctor In 2022, the global market size of prescription drugs was worth $1035.5B and is envisioned to…

ByPrince GiriNovember 21, 2023

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in September 2023

Shots: The EMA approved 11 New Chemical Entity (NCE) and 8 Biologic Drugs in September 2023, leading to treatments for patients and advances in the healthcare industry In September 2023, the major highlight drugs were Litfulo (ritlecitinib) for adolescents and adults with s9ere alopecia areata & Orserdu (elacestrant) for ER+, HER2- locally advanced or metastatic…

BySenior EditorOctober 26, 2023

VIEWPOINTS

Unveiling FDA Acceptance: Ahsan Arozullah of Astellas Dives into Insights on PADCEV sBLAs for UC patients

Shots: Ahsan spoke about the US FDA acceptance for Priority Review of sBLAs for PADCEV and KEYTRUDA to treat patients with LA/mUC who are not eligible to receive cisplatin-containing CT He also talked about the study design and outcomes from the P-Ib/II (EV-103) clinical trial that supported the sBLA. The results from Dose Escalation/Cohort A…

BySenior EditorAugust 17, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in April 2023

Shots: The US FDA approved 6 NDAs and 4 BLA in April 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 36 novel products in 2023 In April 2023, the major highlights drugs were, Trikafta approval for children with cystic fibrosis, Qalsody for the treatment of amyotrophic…

BySenior EditorMay 17, 2023

INSIGHTS+

Disease of the Month: Cervical Cancer

“Get Informed, Get Screened, Get Vaccinated” – WHO Introduction: Cervical cancer is the 4th most common cancer among women and 7th most commonly occurring cancer overall. When a malignant growth or tumor occurs in the cells lining the walls of the cervix, it is called cervical cancer. The cervix is the narrow, lower part of the uterus…

BySenior EditorJanuary 12, 2023

TOP 20

Top 20 Prescription Drugs Based on 2021 Total Revenue

Shots: The pharmaceutical companies have shown continual efforts towards developing enhanced and innovative treatment options to address the unmet needs of patients with disease eradication being the goal of developing these treatments Advancements in cellular and molecular biology have increased the possibilities for generating new pharmaceutical products imposing major impacts on the prevention, diagnosis, and…

ByPrince GiriNovember 10, 2022

INSIGHTS+

Top Performing Drug of 2021 – Keytruda (May Edition)

Active Ingredients: Pembrolizumab Strength: 100 mg/4 mL (25 mg/mL) Dosage Form: Syringe, Vial Mechanism of Action: PD-1 ligands antagonists First Approval: US (Sep 4, 2014), EU (Jul 17, 2015) Revenue Keytruda (pembrolizumab) has been a key player in Merck & Co. immuno-oncology drugs for the past years – reaching nearly $17B in annual sales in 2021. Despite the dampening impact…

BySenior EditorMay 26, 2022

INSIGHTS+

Top Performing Drug of 2021 – Humira (April Edition)

Active Ingredients: Adalimumab Strength: 40 mg/0.8 ml Dosage Form: Syringe, Vial Mechanism of Action: TNF-alpha inhibitors First Approval: US (Dec 31, 2002), EU (Aug 09, 2003) Revenue Humira (adalimumab) has been the top-selling biologic drug product for the last few years – reaching nearly $21B in annual sales in 2021. Humira is one of the main drivers of AbbVie’s immunology…

BySenior EditorApril 29, 2022

INSIGHTS+

Top Performing Drugs of 2021: A Monthly Series by PharmaShots

The year 2021 witnessed the global approval of vaccines and drugs amid COVID-19. The disease has been dominating the headlines from the last two years. No one is amazed that COVID vaccines and drugs find a place in top selling drugs this time. Pfizer & BioNTech’s Comirnaty took the first position with $36B revenue and…

BySenior EditorApril 28, 2022

Insights+: EMA Marketing Authorization of New Drugs in October 2023

Top 20 Prescription Drugs Based on 2022 Total Revenue

Insights+: EMA Marketing Authorization of New Drugs in September 2023

Unveiling FDA Acceptance: Ahsan Arozullah of Astellas Dives into Insights on PADCEV sBLAs for UC patients

Insights+: The US FDA New Drug Approvals in April 2023

Disease of the Month: Cervical Cancer

Top 20 Prescription Drugs Based on 2021 Total Revenue

Top Performing Drug of 2021 – Keytruda (May Edition)

Top Performing Drug of 2021 – Humira (April Edition)

Top Performing Drugs of 2021: A Monthly Series by PharmaShots

Contact US

FOLLOW US